GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » Short Interest

Cereno Scientific AB (FRA:4A1) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Cereno Scientific AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cereno Scientific AB's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cereno Scientific AB's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's Short Interest falls into.


;
;

Cereno Scientific AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » Short Interest
Comparable Companies
OSTO:EQL OSTO:ENZY OSTO:DICOT OSTO:CINPHA OSTO:ORX OSTO:MOB OSTO:KLAR XSAT:ACUC OSTO:NANEXA OSTO:ERMA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
CRNO B:Sweden
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Website
https://www.cerenoscientific.se
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines